Physician profile
William Byron Zipf
NPI 1801974951
$2,103.27
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $688 · 2021: $192 · 2022: $214 · 2023: $365 · 2024: $79.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $823.96 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $186.72 | 2019-2024 | Omnipod |
| Pfizer INC. | $171.10 | 2019-2024 | |
| Abbvie INC. | $160.34 | 2019-2024 | Lupron Depot |
| Novo Nordisk INC | $136.65 | 2019-2024 | Sogroya |
| Arbor Pharmaceuticals, INC. | $93.37 | 2019-2021 | |
| Medtronic, INC. | $63.90 | 2021-2023 | Minimed 780g |
| Abbott Laboratories | $62.45 | 2020-2023 | Freestyle Libre |
| Dexcom, INC. | $58.39 | 2021-2022 | |
| Lilly USA, LLC | $46.65 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $44.55 | 2023 | Triptodur |
| Endo Pharmaceuticals INC. | $32.59 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $31.73 | 2019-2020 | |
| Medtronic Minimed, INC. | $30.61 | 2019 | |
| Ascendis Pharma Endocrinology INC | $24.90 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eton Pharmaceuticals, INC. | $24.79 | 2023 | Alkindi |
| Sanofi-Aventis U.S. LLC | $23.05 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $19.40 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.18 | 2021 | |
| Biomarin Pharmaceutical INC. | $17.80 | 2022 | |
| Ferring Pharmaceuticals INC. | $16.55 | 2020 | |
| Rhythm Pharmaceuticals, INC. | $15.59 | 2023 | Imcivree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Zipf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.